Overview

A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
0
Participant gender:
All
Summary
This study will assess the efficacy and safety of treatment with the combination Avastin (bevacizumab) 5mg/kg iv every 2 weeks, Xeloda (capecitabine) 1000 mg po b.i.d. on Days 1-14 of every 28-day cycle and oxaliplatin 40mg/m2 iv weekly in patients with inoperable locally advanced or metastatic colorectal cancer. The anticipated time on study treatment is until disease progression.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Bevacizumab
Capecitabine
Oxaliplatin
Criteria
Inclusion Criteria:

- Adult patients >=18 years of age

- Locally advanced or metastatic colorectal cancer

- No previous treatment with chemotherapy for metastatic disease

- Measurable and/or evaluable lesions

Exclusion Criteria:

- Radiotherapy within 4 weeks before study

- Untreated brain metastases or primary brain tumors

- Chronic, daily treatment with high-dose aspirin (>325mg/day)

- Co-existing malignancies, or malignancies diagnosed within the last 5 years, with the
exception of basal and squamous cell cancer, or cervical cancer in situ